MATF is one of the only high throughput production facilities in the world offering custom-made, high quality, high-affinity monoclonal antibodies.
18 Aug 2016
Monash Partners Accredited ICH Research Good Clinical Practice (GCP) Training Program
From August 2016, Monash University will offer TransCelerate accredited ICH Good Clinical Practice Training in clinical research, expected and recognised by pharmaceutical companies in commercially-sponsored clinical trials. ICH GCP is also increasingly a requirement of human research and ethics committees
25 Oct 2016
Circulating biomarkers in metastatic prostate cancer
MPCCC and BDI present this Biomedicine Discovery Seminar featuring guest speaker Dr Arun Azad presenting the topic Circulating biomarkers in metastatic prostate cancer
29 Sep 2016
How can we predict whether Angelina Jolie would have developed breast cancer? Recent findings from the Consortium of Investigators of Modifiers of BRCA1/2
MPCCC and BDI present this Biomedicine Discovery Seminar featuring guest speaker Professor Georgia Chenevix-Trench, Head of the Cancer Genetics Laboratory and the Department of Genetics and Computational Biology at the QIMR Berghofer in Brisbane
02 Dec 2016
The Monash University Centre for Human Bioethics is pleased to announce the 32nd running of its annual Intesive Bioethics Course on 2–5 December 2016.
DHHS to pilot collection of Patient Reported Outcome Measures
The Victorian Department of Health and Human Services has announced that it will pilot the collection of Patient Reported Outcome Measures (PROMs) from health services and hospitals from 1 July 2017.
Breakthrough heralds hope for advanced bladder cancer patients
Researchers at Hudson Institute of Medical Research have discovered a crucial genetic marker that heralds better treatment and outcomes for patients with advanced bladder cancer.
Key differences in tumours could help tackle ovarian cancer recurrence
A new study by Hudson Institute of Medical Research and Fiona Elsey Cancer Research Institute scientists has uncovered important differences between pre- and post- chemotherapy ovarian cancer tumours that may be used to better tackle chemotherapy resistance.
Cell Therapies Platform and Miltenyi Biotec Cell Therapy Centre of Excellence launched at MHTP
A new Cell Therapies Platform was officially launched at the Monash Health Translation Precinct (MHTP) at the end of August and will play a vital role in accelerating translational research leading to the development of new treatments for diseases such as cancer.